BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 31023030)

  • 41. Correlation of myeloid-derived suppressor cells with C-reactive protein, ferritin and lactate dehydrogenase levels in patients with severe COVID-19.
    Emsen A; Sumer S; Tulek B; Cizmecioglu H; Vatansev H; Goktepe MH; Kanat F; Koksal Y; Arslan U; Artac H
    Scand J Immunol; 2022 Jan; 95(1):e13108. PubMed ID: 34625989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients.
    Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E
    Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma.
    Yokota S; Yonezawa T; Momoi Y; Maeda S
    Vet Immunol Immunopathol; 2024 Mar; 269():110716. PubMed ID: 38308864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer.
    OuYang LY; Wu XJ; Ye SB; Zhang RX; Li ZL; Liao W; Pan ZZ; Zheng LM; Zhang XS; Wang Z; Li Q; Ma G; Li J
    J Transl Med; 2015 Feb; 13():47. PubMed ID: 25638150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myeloid-Derived Suppressor Cells Promote the Progression of Primary Membranous Nephropathy by Enhancing Th17 Response.
    Li H; Wu H; Guo Q; Yu H; Xu Y; Yu J; Wang Z; Yi H
    Front Immunol; 2020; 11():1777. PubMed ID: 32973748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
    Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
    Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
    Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
    Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells.
    Lim JY; Kim TW; Ryu DB; Park SS; Lee SE; Kim BS; Min CK
    Cancer Immunol Res; 2021 May; 9(5):503-513. PubMed ID: 33771821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RNA-Seq Analysis of Colorectal Tumor-Infiltrating Myeloid-Derived Suppressor Cell Subsets Revealed Gene Signatures of Poor Prognosis.
    Saleh R; Sasidharan Nair V; Al-Dhaheri M; Khawar M; Abu Nada M; Alajez NM; Elkord E
    Front Oncol; 2020; 10():604906. PubMed ID: 33312958
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers.
    Lim HX; Kim TS; Poh CL
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses.
    Kontaki E; Boumpas DT; Tzardi M; Mouzas IA; Papadakis KA; Verginis P
    Autoimmunity; 2017 May; 50(3):170-181. PubMed ID: 28276713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer.
    Kobayashi T; Nagata M; Hachiya T; Wakita H; Ikehata Y; Takahashi K; China T; Shimizu F; Lu J; Jin Y; Lu Y; Ide H; Horie S
    Front Immunol; 2024; 15():1372771. PubMed ID: 38887300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
    Wen J; Huang G; Liu S; Wan J; Wang X; Zhu Y; Kaliney W; Zhang C; Cheng L; Wen X; Lu X
    J Pathol Clin Res; 2020 Jul; 6(3):171-177. PubMed ID: 32149481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.
    Sui Y; Frey B; Wang Y; Billeskov R; Kulkarni S; McKinnon K; Rourke T; Fritts L; Miller CJ; Berzofsky JA
    PLoS Pathog; 2017 May; 13(5):e1006395. PubMed ID: 28498847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
    Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
    Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
    Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
    Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.